Table 3.
Omalizumab exposure, pregnancy, and infants outcomes.
| Omalizumab exposure | |
|---|---|
| Time before pregnancy (months) (mean ± SD) | 28.9 ± 22.3 |
| Dose (mg) | |
| 150 (N and %) | 4 (18.2%) |
| 225 (N and %) | 2 (9.1%) |
| 300 (N and %) | 11 (50%) |
| 375 (N and %) | 2 (9.1%) |
| Other (N and %) | 3 (13.6%) |
| Dose interval | |
| Every 2 weeks (N and %) | 5 (22.7%) |
| Every 4 weeks (N and %) | 17 (77.3%) |
| Exposure time | |
| 1st trimester (N and %) | 3 (13.6%) |
| 2nd trimester + 3rd trimester (N and %) | 4 (18.2%) |
| All trimesters and breastfeeding period (N and %) | 16 (69.6%) |
| Pregnancy and infant outcomes | |
| Birth weight (mg) (mean ± SD) | |
| All infants | 3055.8 ± 563.3 |
| Singletons | 3109.1 ± 540.3 |
| Twins | 2062.5 ± 12.5 |
| Low birth weight* (N and %) | |
| All infants | 3 (13.04%) |
| Singletons | 1 (4.76%) |
| Twins | 2 (100%) |
| Birth height (cm) (mean ± SD) | 48.2 ± 3.7 |
| Gestational age (weeks) (mean ± SD) | 37.3 ± 2.2 |
| Premature birth** (N and %) | 5 (21.7%) |
| Sex: male/female (N and %) | 9/14 (39.1/60.9%) |
| APGAR Score | |
| Median (range: min–max) | 9 (5–10) |
| Low APGAR score*** (N and %) | 1 (4.76%) |
| Infants with any allergic diseases (N and %) | 6 (26.09%) |
| Actual age of infants (weeks) (mean ± SD) (range) | 31.2 ± 28.9 (range: 7–120) |
*Low birth weight was defined as <2.5 kg.